Drug Approval | April 14, 2026
CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
In his new role, he is expected to further strengthen Zenex Animal Health’s market position and accelerate its next phase of growth.
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Subscribe To Our Newsletter & Stay Updated
